Tiziana Life Sciences Announces Purchase of Shares by Chairman

Core Insights - Tiziana Life Sciences Ltd. is focused on developing immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody [1][4] - The Executive Chairman, Mr. Gabriele Cerrone, has increased his stake in the company by purchasing 15,000 shares at $1.55 each, now holding 43,252,143 shares, which constitutes 37.02% of the total issued share capital [1] Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company that aims to develop innovative therapies using advanced drug delivery technologies, particularly focusing on alternative routes for immunotherapy [4] - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in previous studies [4] Product Development - Foralumab has been administered to 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) in an open-label Expanded Access Program, with all patients showing either improvement or stability of disease within 6 months [2] - A Phase 2a trial for intranasal foralumab began screening patients in November 2023, focusing on its efficacy in treating non-active secondary progressive multiple sclerosis [3] Innovation and Technology - Tiziana's nasal delivery approach is expected to enhance both efficacy and safety compared to traditional intravenous delivery methods, potentially leading to broader applications in immunotherapy [4] - The company has patented its technology for alternative routes of immunotherapy, with several applications pending, indicating a strong pipeline for future developments [4]